339 related articles for article (PubMed ID: 30257889)
1. Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer.
Wu B; Gu X; Zhang Q; Xie F
Oncologist; 2019 Mar; 24(3):349-357. PubMed ID: 30257889
[TBL] [Abstract][Full Text] [Related]
2. Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada.
Ezeife DA; Kirk V; Chew DS; Nixon NA; Lee R; Le LW; Chan KK; Leighl NB
Lung Cancer; 2018 Nov; 125():1-7. PubMed ID: 30429004
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia.
Khoo T; Gao L
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):415-423. PubMed ID: 33151783
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China.
Guan H; Liu G; Xie F; Sheng Y; Shi L
Clin Ther; 2019 Nov; 41(11):2308-2320.e11. PubMed ID: 31607559
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China.
Cai H; Zhang L; Li N; Chen S; Zheng B; Yang J; Weng L; Liu MB
Clin Ther; 2019 Feb; 41(2):280-290. PubMed ID: 30639208
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore.
Aziz MIA; Foo WYX; Toh CK; Lim WT; Ng K
J Med Econ; 2020 Nov; 23(11):1330-1339. PubMed ID: 32886557
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR TKI Therapy.
Wu B; Gu X; Zhang Q
J Thorac Oncol; 2018 Feb; 13(2):184-193. PubMed ID: 29101057
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients.
Li WQ; Li LY; Chai J; Cui JW
Cancer Med; 2021 Mar; 10(6):1964-1974. PubMed ID: 33626238
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
Aguiar PN; Haaland B; Park W; San Tan P; Del Giglio A; de Lima Lopes G
JAMA Oncol; 2018 Aug; 4(8):1080-1084. PubMed ID: 29852038
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of Osimertinib vs Docetaxel-bevacizumab in Third-line Treatment in EGFR T790M Resistance Mutation Advanced Non-Small Cell Lung Cancer in China.
Rui M; Li H
Clin Ther; 2020 Nov; 42(11):2159-2170.e6. PubMed ID: 33028495
[TBL] [Abstract][Full Text] [Related]
11. Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis.
Aguilar-Serra J; Gimeno-Ballester V; Pastor-Clerigues A; Milara J; Marti-Bonmati E; Trigo-Vicente C; Alós-Almiñana M; Cortijo J
J Comp Eff Res; 2019 Aug; 8(11):853-863. PubMed ID: 31478399
[No Abstract] [Full Text] [Related]
12. Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer.
Bertranou E; Bodnar C; Dansk V; Greystoke A; Large S; Dyer M
J Med Econ; 2018 Feb; 21(2):113-121. PubMed ID: 28880737
[TBL] [Abstract][Full Text] [Related]
13. Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset.
Cho BC; Chewaskulyong B; Lee KH; Dechaphunkul A; Sriuranpong V; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cheng Y; Cho EK; Voon PJ; Lee JS; Mann H; Saggese M; Reungwetwattana T; Ramalingam SS; Ohe Y
J Thorac Oncol; 2019 Jan; 14(1):99-106. PubMed ID: 30240852
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations.
Holleman MS; Al MJ; Zaim R; Groen HJM; Uyl-de Groot CA
Eur J Health Econ; 2020 Feb; 21(1):153-164. PubMed ID: 31541309
[TBL] [Abstract][Full Text] [Related]
15. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.
Cheng Y; He Y; Li W; Zhang HL; Zhou Q; Wang B; Liu C; Walding A; Saggese M; Huang X; Fan M; Wang J; Ramalingam SS
Target Oncol; 2021 Mar; 16(2):165-176. PubMed ID: 33544337
[TBL] [Abstract][Full Text] [Related]
16. Incremental cost-effectiveness analysis of tyrosine kinase inhibitors in advanced non-small cell lung cancer with mutations of the epidermal growth factor receptor in Colombia.
Lasalvia P; Hernández F; Gil-Rojas Y; Rosselli D
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):821-827. PubMed ID: 32498573
[TBL] [Abstract][Full Text] [Related]
17. Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations.
Westerink L; Nicolai JLJ; Samuelsen C; Smit HJM; Postmus PE; Griebsch I; Postma MJ
Eur J Health Econ; 2020 Aug; 21(6):931-943. PubMed ID: 32328874
[TBL] [Abstract][Full Text] [Related]
18. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K
Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754
[TBL] [Abstract][Full Text] [Related]
19. Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient.
Yang Z; Yang J; Chen Y; Shao YW; Wang X
Target Oncol; 2019 Aug; 14(4):369-374. PubMed ID: 31301016
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of different sequences of osimertinib administration for epidermal growth factor receptor-mutated non-small-cell lung cancer.
Li W; Qian L; Li W; Chen X; He H; Tian H; Zhao Y; Wang X; Cui J
Exp Ther Med; 2021 Apr; 21(4):343. PubMed ID: 33732316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]